Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Help your infant or toddler cope with stressful events

  • Autistic brain less flexible at taking on tasks

  • Social origins of intelligence in the brain

  • Preterm children's brains can catch up years later

  • Toward an oral therapy for treating Alzheimer's disease: Using a cancer drug

  • Glucose 'control switch' in the brain key to both types of diabetes

  • Novel technologies advance brain surgery to benefit patients

  • Immune response may cause harm in brain injuries, disorders

  • Targeting the brain to treat obesity

  • Klotho: neuroprotective against Alzheimer's disease

  •